Dexmedetomidine for Preventing Postoperative Delirium and a Risk Prediction Nomogram in Older Adults Undergoing Gastrointestinal Surgery
A legfontosabb adatok
- Ki végzi
- Hanoi Medical University
- Hol
- Vietnám1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 630 fő, tervezett
- Kezdés
- 2026. dec. 1.
- Várható befejezés
- 2028. ápr. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Dexmedetomidine
- Placebo
- A regiszteradat frissítve
- 2026. november 17.
Ki vehet részt
- Életkor
- 60 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki vehet részt
- Age 60 years or older
- Scheduled for elective gastrointestinal surgery (esophageal, gastroduodenal, small bowel, colorectal, hepatobiliary, pancreatic or splenic) under general anesthesia
- American Society of Anesthesiologists (ASA) physical status I-III
- Written informed consent from the patient, or from a legally authorized representative if the patient lacks decision-making capacity
Ki nem vehet részt
- Expected duration of surgery < 90 minutes
- Substance dependence or abuse, or current use of antipsychotic medication
- Refusal by the patient or family to participate; Withdrawal criteria (after randomization): severe anesthetic or surgical complications (e.g., anaphylaxis, local anesthetic systemic toxicity, hemorrhagic shock); premature discontinuation of study drug due to adverse effects; actual surgical duration < 90 minutes; postoperative mechanical ventilation > 24 hours; re-anesthesia, spinal anesthesia or reoperation during the study period; withdrawal of consent. Patients withdrawn after starting the infusion remain in the mITT analysis
- Severe preoperative cognitive impairment (Mini-Mental State Examination score < 14)
- Contraindications to dexmedetomidine: known allergy, bradycardia, second- or third-degree atrioventricular block without a pacemaker, or current high-dose beta-blocker therapy
- Hepatic failure (Child-Pugh class B or C) or end-stage renal disease requiring dialysis
- Cancer with brain or bone metastases causing severe preoperative pain
- Preoperative delirium
- Communication difficulties preventing completion of study assessments
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Postoperative delirium (POD) is a common and serious complication in older adults after major gastrointestinal surgery and is associated with longer hospital stay, long-term cognitive decline and higher mortality. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist with sedative, anti-inflammatory and opioid-sparing effects, may reduce POD, but evidence in older patients undergoing gastrointestinal surgery remains inconsistent, and tools to identify which patients are at highest risk are lacking.
A teljes eredeti leírásKevesebb
The goal of this randomized, double-blind, placebo-controlled trial is to learn whether intraoperative and early postoperative dexmedetomidine prevents POD in patients aged 60 years or older undergoing elective gastrointestinal surgery under general anesthesia, and to develop a risk prediction nomogram for POD in this population. The main questions it aims to answer are:
1. Does dexmedetomidine lower the incidence of POD within 5 days after surgery compared with placebo, and is it safe? 2. How accurately can a prediction model (nomogram) built from preoperative and intraoperative factors estimate each patient's risk of POD?
Researchers will also examine how dexmedetomidine changes postoperative inflammatory and stress markers (IL-6, cortisol, CRP, NLR, SII) and their association with POD, and whether the benefit of dexmedetomidine differs across baseline-risk strata.
Participants will be randomly assigned to dexmedetomidine or placebo (0.9% saline). The blinded infusion starts 15 minutes before induction of anesthesia (dexmedetomidine 0.5 mcg/kg over 15 minutes, then 0.5 mcg/kg/h until 2 hours after surgery, or the same volume and rate of saline). Delirium will be assessed three times daily with the 3D-CAM (or CAM-ICU for patients who cannot be interviewed) from the end of surgery until postoperative day 5 or hospital discharge.
A vizsgálat 2 csoportja
- DexmedetomidineA vizsgált kezelés
Dexmedetomidine 4 mcg/mL (200 mcg in 50 mL 0.9% saline). Loading dose 0.5 mcg/kg infused over 15 minutes starting 15 minutes before induction of general anesthesia, followed by a maintenance infusion of 0.5 mcg/kg/h throughout surgery until 2 hours after the end of surgery.
- Placebo (0.9% saline)Placebo, összehasonlításként
0.9% sodium chloride 50 mL in an identical syringe, infused at the same volume, rate and duration as the dexmedetomidine arm (15-minute loading infusion before induction, then maintenance until 2 hours after the end of surgery).
Kezelés: Placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Efficacy of Dexmedetomidine in Preventing Postoperative Delirium and a Risk Prediction Nomogram in Geriatric Patients Undergoing Gastrointestinal Surgery: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial
- A regiszteradat frissítve
- 2026. november 17.